Adrenocortical carcinoma (ACC) accounts for a minority of all malignant tumors in adults.
Surgery remains the most important therapeutic option for non-metastatic ACC. Whether a …

Approximately one-tenth of the general population exhibit adrenal cortical nodules, and the
incidence has increased. Afflicted patients display a multifaceted symptomatology …

Background Adrenocortical carcinoma (ACC) is an extremely rare, aggressive tumor with
few effective therapeutic options or drugs. Mitotane (Mtn), which is the only authorized …

Unlike most cancers, adrenocortical carcinomas (ACCs) are more frequent in women than in
men, but the underlying mechanisms of this sexual dimorphism remain elusive. Here, we …

Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for
treating adrenocortical carcinoma (ACC). This drug has cytotoxic effects on tumour tissues; it …

The adrenal glands are paired endocrine organs that produce steroid hormones and
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy arising from the adrenal
cortex often with unexpected biological behavior. It can occur at any age, with two peaks of …

Adrenal cortex produces glucocorticoids, mineralocorticoids and adrenal androgens which
are essential for life, supporting balance, immune response and sexual maturation …

Adrenocortical carcinoma (ACC) is a rare malignancy characterized by aggressive biology
and potential endocrine activity. Surgery can offer cure for localized disease but more than …

Simple Summary Mitotane is the only approved drug for the treatment of advanced
adrenocortical carcinoma and for postoperative adjuvant therapy. It is known that mitotane …